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Abstract
Background: Drug addiction is associated with significant disease and death, but its impact on the
ageing process has not been considered. The recent demonstration that many of the items available
in routine clinical pathology have applicability as biomarkers of the ageing process implies that
routine clinical laboratory parameters would be useful as an initial investigation of this possibility.
Methods: 12,093 clinical laboratory results 1995–2006 were reviewed. To make the age ranges of
the medical and addicted groups comparable the age range was restricted to 15–45 years.
Results: 739 drug addicted (DA) and 5834 general medical (GM) age matched blood samples were
compared. Significant elevation of immune parameters was noted in the C-reactive protein,
erythrocyte sedimentation rate, total lymphocyte count, serum globulins and the globulin:albumin
ratio (P < 0.01). Alanine aminotranferase, creatinine, urea, and insulin like growth factor-1 were
also significantly higher (P < 0.01) in the DA group. Albumin, body mass index and
dihydroepiandrosterone sulphate were unchanged and cholesterol was lower (all P < 0.05).
Conclusion: These data demonstrate for the first time that addiction is associated with an altered
profile of common biomarkers of ageing raising the possibility that the ageing process may be
altered in this group. Infective and immune processes may be centrally involved. They suggest that
addiction forms an interesting model to further examine the contribution of immune suppression
and hyperstimulation to the ageing process.
Background
Addictive disorders are well known to be associated with
a high level of physical and psychological disorders [1].
Most chronic chemical addictions are also associated with
very elevated rates of mortality [2] which have been esti-
mated to be 10–70 [3,4] times that of non-clinical popu-
lations. Addictive drugs are known to impair cell growth
and division [5-7] and therefore might be presumed to
impact particularly dividing cells such as stem and pro-
genitor cell pools [8,9]. They are also known either singly
or in combination to potentiate apoptosis [10-14] thereby
adding to this effect. Ageing medicine has recently
emerged as a distinct scientific discipline. The cellular
hypothesis of ageing suggests that the ageing phenotype
of the organism is associated with cellular correlates of age
related change including cell loss, reduced rates of cell
renewal, and higher numbers of senescent, marginally
functional, and non-replicative cells in the tissues [15,16].
Therefore if the growth inhibitory effects of addiction
occur throughout the organism, one might reasonably
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expect that signs of accelerated ageing may be evident.
Such a putative progeroid effect might be expected to
underlie the elevated rates of morbidity and mortality
observed clinically amongst addicts in much the same
way as they do in geriatric populations. In this connection
it is relevant that a variety of changes consistent with such
a pro-ageing effect [17] have been reported both from our
own clinic and elsewhere, and relating to neuropsychiatric
disorders [18-20], calcific [21] and degenerative[22] arte-
riosclerosis, osteoporosis[23,24], oligospermia [25,26],
hair greying [27] and severe dental and periodontal
pathology [28,29]. Consideration of all of the clinical
expressions of this generic hypothesis of the toxicology of
addiction is beyond the scope of the present investigation.
The immune system in particular is central to a consider-
ation of ageing. The immune system of drug dependent
individuals is known to be suppressed, dysfunctional and
hyperstimulated [30-34], and these perturbations are the
subject of on-going enquiry. Not only does the immune
system itself demonstrate age related change [35,36], but
the ready access of its cells and cytokines to most parts of
the body including the CNS in many inflammatory dis-
ease states, suggests that dysfunction in this system might
potentially be an important mediator and contributor to
putative age related processes including atherosclerotic
[37] and neurodegenerative [38] disorders as well as a
major source of free radicals [39]. Some chemical addic-
tions have also been associated with free radical genera-
tion [40,41].
The potential implications of an improved understanding
of the pathophysiology of addiction may have several
clinically relevant implications. There is intense interest
from the National Institutes of Ageing and others in the
development of anti-ageing medicines (such as resveratrol
and diaformin) [42] and it may be that such agents come
to have a role in the treatment of the addictions. Con-
versely research in anti-ageing medicines has fuelled vig-
orous interest in various biomarkers as surrogate end
points for otherwise lengthy clinical trials of putative
agents [43]. Conveniently many of the common biomar-
kers are readily available in clinical pathology laboratory
parameters in widespread use. If the classical chemical
addictions are shown to accelerate ageing, then clearly
there may be a role for their antagonists (such as the opi-
oid antagonists naltrexone and nalmefene and cannabi-
noid antagonists such as rimonabant) which are largely
pro-mitotic, as anti-ageing therapies if a deleterious effect
on cancer can be avoided. And clearly a better understand-
ing of the mechanism by which the various chemical
addictions act to induce the aged phenotype may enhance
our understanding of the basic pathophysiology of the
ageing process itself, including gametotoxic and develop-
mental implications.
My clinic sees both medical patients and patients addicted
(mainly to opiates) and so provides an opportunity to
compare relevant states of health and disease in these two
populations. The present paper is presented as an initial
clinical study of this subject and is intended to stimulate
further investigative interest in the possible progeroid
effects of addiction based on readily available clinical
information relating to infective episodes and laboratory
pathology.
Methods
Patient Recruitment, Survey and Sampling
This primary care medical centre operates in inner city
Brisbane and sees both general medical (GM) and drug
addicted (DA) patients. Most of our work involves the
treatment of opiate addicted persons, and this is under-
taken predominantly with the buprenorphine/naloxone
combination sublingual tablet. Blood samples were taken
opportunistically on patients as part of their routine clin-
ical care.
Laboratory Analysis
Specific haematological and biochemical data of interest
was requested from our commercial clinical pathology
laboratories for our patients in the period 1995–2006.
Assays were done by standard clinical laboratory meth-
ods. The clinical laboratories used were Queensland Med-
ical Laboratories (QML) and Mater Hospitals (MAH)
Pathology Laboratories both in Brisbane, Queensland,
Australia. Both laboratories are accredited within Aus-
tralia by the National Association of Testing Authorities
(NATA) to the current Australian medical laboratory
standards (AS-15189), and QML is accredited to ISO 9001
the international clinical laboratory standard. 96% of the
work was done at QML, and 4% at MAH. GM and DA
samples were sent equally to both laboratories. All pathol-
ogy samples were sent to QML prior to June 2006, and to
MAH after that time. Where available results from both
sites were combined unless the normal range or distribu-
tion of the results were significantly different so that arte-
factual differences were introduced into the analysis. In
such cases, only the larger dataset was used. When data
from the two laboratories was combined, care was taken
not to alter the pattern of results. Reported data for albu-
min were based only on QML data. In other cases data
from the two laboratories was directly combined. The nor-
mal ranges for the two laboratories are included in Table
1. Data for DHEAS and IGF1 are not included as they are
age and sex dependent and vary substantially over the
lifespan. The normal ranges for these two parameters in
the two laboratories were thought to be similar.
Data Analysis and Statistics
Data was entered into Excel spreadsheets. Data is listed as
mean ± S.D. or S.E. as indicated. Statistical analysis wasImmunity & Ageing 2007, 4:6 http://www.immunityageing.com/content/4/1/6
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performed using the EpiInfo program obtained from Cen-
tres for Disease Control for Chi squared comparisons of
paired categorical data to calculate relative risks, 95% con-
fidence intervals and significance levels; quantitative data
was analyzed using T-tests performed in Microsoft Excel;
and graphs were presented using the statistical software
package "Statistica" on a Dell personal computer. Clinical
pathology results were made available in electronic for-
mat. DA were sorted from GM patients by the presence of
a Hepatitis C test, a test which is limited almost com-
pletely to use in DA patients. No data (such as outliers)
was excluded from the analysis.
Ethical Approval
All procedures and studies were consistent with good clin-
ical practice as defined by the National Health and Medi-
cal Research Council and the Declaration of Helsinki and
were approved by the approved by the Human Research
Ethics Committee of the Southcity Family Medical Centre.
Patients gave informed consent to participation in the
study. No external source of funding was involved.
Results
The age and sex distribution of the two groups is given in
Table 2. In this study 798 DA and 11295 GM blood sam-
ples from patients of all ages were available for analysis.
However, as indicated in Table 2 again problems of age
disparity between the two groups were encountered.
Therefore the age range was restricted to 15–45 years, leav-
ing 739 and 5834 samples for consideration. The resulting
mean ages (± S.E.) were 30.92 ± 0.24 and 30.74 ± 0.11
years respectively (P – N.S.).
The present data was not linked to a detailed drug use his-
tory. DA patients presented for management of opiate
addiction, where the primary substance of abuse was 86%
heroin, 12% morphine, 1% buprenorphine and 1%
methadone. More detailed information relating to drug
use by this cohort has been previously published and is
included for convenience in Table 3. Only 1% of each
group was HIV positive.
A study of this nature is predicated on being able to relia-
bly separate intravenous drug using (IVDU) DA from GM.
Review of 100 samples from each group found a 1% and
3% error rate respectively in group assignment based on
HCV status. Furthermore the HCV positivity rate in the DA
group was 69%, which accords well with 70% as previ-
ously found in studying DA in our clinic, suggesting min-
imal contamination and dilution of the IVDU DA group.
Figures 1 and 2 demonstrates the lifetime trends for the
variables of interest, namely CRP, ESR, globulins, albu-
min, globulin/albumin ratio, total lymphocyte count,
ALT, cholesterol, urea, creatinine, dihydroepiandroster-
one (DHEAS) and insulin like growth factor-1 (IGF1)
together with their lines of best fit. Similar curves may be
generated for the period of interest 15–45 years and these
are included as Additional File 1. These two figures are
best viewed together. The data is quantified in Table 4,
and the relative fractions which are elevated either above
normal or beyond a certain limit are given in Table 5.
There is little relative change in the CRP, although it was
shown that 52.6% of DA Vs. 37.7% of GM had elevated
CRP (OR = 1.84, CI 1.30–2.60; P < 0.0005). The ESR
showed an obvious rise in the <45 years comparison con-
firmed by a higher mean (± S.E.) 11.34 ± 1.29) vs. 8.75 ±
0.35, P = 0.05, with more elevated values (7.7% Vs. 4.1%,
OR = 1.98, OR = 1.98, CI 1.00–3.87; P < 0.05). Serum
globulins showed an obvious rise with age with a higher
mean in DA 30.33 ± 0.19 Vs. 29.47 ± 0.05 with 14.8% Vs.
9.3% elevated (OR = 1.70 CI 1.32–2.18; P < 0.002). The
albumin levels were identical in both groups, so the glob-
ulin/albumin ratio rose in DA over both the total lifespan
and particularly in the <45 years group (14.8% Vs. 9.3%
>6.5, OR = 1.69, CI 1.21–2.21; P < 0.002). The lym-
phocyte count in the GM patients showed the usual
decline with age. However, this was absent from the DA
group, where the lymphocyte count remained stable
throughout life. Hence the mean lymphocyte count was
higher in the DA 2.41 ± 0.03 Vs. 2.26 ± 0.01 × 109/l and
Table 2: Demographic data
PARAMETER ADDICTS MEDICAL (TOTAL/) 
SIGNIFICANCE
All Sample Size 
(Total)
798 11295 12093
Age as Mean(SD) 31.95 (8.39) 46.66 (19.18) <0.0001
Sample Size <45 
Years (Total)
739 5834 6573
Age 30.92 (6.52) 30.74 (8.63) N.S.
% Male 73.5% 54.3% <0.0001
Data as mean ± S.D.
Table 1: Normal ranges of clinical laboratory parameters
PARAMETER QML Range MAH Range
CRP (IU/l) 1–6 1–6
ESR (mm/hr) 1–25 1–25
Albumin (g/l) 35–50 33–47
Globulins (g/l) 20–40 20–40
Lymphocytes (*109/l) 1.1–4.0 1.0–4.8
ALT (U/l) 0–45 5–45
Cholesterol (mmol/l) 3.1–6.5 2.6–5.5
Urea (mmol/l) 2.0–7.0 3.0–8.0
Creatinine (mcmol/l) 40–110 70–120Immunity & Ageing 2007, 4:6 http://www.immunityageing.com/content/4/1/6
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more DA had a lymphocyte count above 2.5 × 109/l
(37.3% Vs. 31.8%, OR = 1.27, CI 1.06–1.53; P < 0.01).
The body mass index was not different between the two
groups (Additional File 1, Table 5). ALT is significantly
higher in the DA group by all measures. The mean DA
cholesterol (4.48 ± 0.04 mmol/l) is less than that in GM
(4.77 ± 0.14; P < 0.0001), but as noted the albumin is
unchanged between the two groups. The urea and creati-
nine are both higher in DA, and elevated ratios of urea to
creatinine are more common in the DA group 11.0% Vs.
5.3% (OR = 2.78, CI 2.11–3.65; P < 0.0001).
IGF1 was higher in the DA group. The rate of IGF1 above
30 was greater in DA (OR = 3.66, CI 1.70–7.91; P <
0.002). DHEAS levels were not different overall, or in any
of the age and sex groups examined. As it is an androgen,
with higher levels in males particularly during adult years,
a detailed graphical analysis of these data is presented in
Figure 3.
Discussion
These data demonstrate in HIV negative populations that
addicted patients have a clinical pathological profile of
immune stimulation (higher ESR, CRP, globulins, globu-
lin:albumin ratio, lymphocyte count) in the setting of
hepatic (higher ALT and lower cholesterol) and renal
(higher urea, creatinine and urea:creatinine ratio) dys-
function. The body mass index and albumin were similar
in the two groups suggesting nutritional adequacy in the
DA group. The DHEAS showed no overall between group
variation, but interesting differences in patients less than
45 years. Interestingly the IGF1 appeared better in the DA
group.
The major finding of this study is that as these various
parameters have been suggested as important biomarkers
of the ageing process, they form together a highly sugges-
tive pattern of findings that the ageing process in addic-
tion might be following a different time trajectory from
medical patients. They also suggest that the known
immune derangements of addiction may be playing a role
in the observed systemic perturbations.
There is a large literature particularly coming from the
study of centenarians in Italy which posits that chronic
antigenic stress exerts a strain on the immune system, uses
up all the naïve T-cells and causes long term CD4 and
CD8 memory cells to accumulate [44-52]. In part this is
believed to occur via free radical stimulation of P16INK4A
dependent apoptosis [53]. It is fascinating to consider that
all these circumstances pertain in addiction. In the
absence of HIV infection chronic antigenic stimulation in
addiction can originate from dental, bronchial and cuta-
neous foci, from chronic hepatic inflammation and viral
shedding, from the use of drugs, and the endobronchial
absorption and intravascular injection of particulate sub-
stances all of which are directly active on immune cells
and the injection of particulate impurities including
microbial organisms and antigens. Hence the situation in
addiction closely parallels that in ageing, as both demon-
strate chronic antigenic overload, immune stimulation,
immunosuppression and signs of accelerated ageing.
Hence the immune system may not only be a spectator in
both the ageing process and in addiction, but a major
effector of time dependent decay. Clearly these parallels
require more detailed prospective investigation.
It is also interesting to speculate on the interrelationship
between the immune stimulation and solid organ dys-
function documented in the pathological study. The liver
in particular is known to harbor a substantial body of
immune (Kupffer) cells and endothelial cells in its sinu-
soids, and their interaction with and response to systemic
alterations may be more than passive. Both the immune
and endothelial components are believed to be important
in modern theories of ageing. This is particularly relevant
in a context where the liver is receiving long term irritation
through alcohol, intravenous injection, drug detoxifica-
tion or chronic viral infection. Clearly several drug related
factors must inform the use of the ALT as an uncompli-
Table 3: Drug use
PARAMETER ADDICTS MEDICAL
Dose & Duration
Cigarette Numbers 16.08 (10.87) 4.36 (8.12)***
Cigarette Duration (Yrs) 13.83 (8.62) 3.77 (8.145)***
Alcohol Size (g/d) 8.65 (21.51) 1.77 (10.23)***
Alcohol Duration (Yrs) 2.97 (5.84) 0.96 (3.08)***
Cannabis Size (g/d) 2.71 (5.25) 0.34 (1.56)***
Cannabis Duration (Yrs) 7.27 (7.57) 0.81 (3.24)***
Heroin Size (g/d) 0.57 (1.01) 0.00***
Heroin Duration (Yrs) 8.97 (6.92) 0.00***
Morphine Size (g/d) 0.05 (0.20) 0.00***
Morphine Duration (Yrs) 1.19 (4.12) 0.00***
Methadone Max. Dose 27.53 (47.19) 0.00***
Methadone Duration (Yrs) 1.21 (3.05) 0.00***
Amphetamine Size (g/d) 0.55 (1.51) 0.02 (0.15)***
Amphetamine Duration 
(Yrs)
1.89 (4.29) 0.19 (1.31)***
Dose-Duration Products
Cigarette Index (Cig-Yrs) 256.25 (217.70) 69.26 (164.68)****
Alcohol Index (g-Yrs) 73.49 (219.19) 21.89 (132.79)*
THC Index (g-Yrs) 28.99 (62.87) 3.31 (14.53)****
Heroin Index (g-Yrs) 5.92 (11.06) 0****
Morphine Index (g-Yrs) 0.39 (1.57) 0***
Methadone Index (mg-Yrs) 114.26 (373.82) 0****
Amphetamine Index (g-Yrs) 1.39 (10.17) 0.19 (1.31)****
Data as Mean (± S.D.)
* – P < 0.05
*** – P < 0.001
**** – P < 0.0001Immunity & Ageing 2007, 4:6 http://www.immunityageing.com/content/4/1/6
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cated biomarker of ageing in the context of addiction.
Albumin is synthesized in the liver but was found to be
identical in the two groups. Cholesterol, although not dif-
ferent in DA and GM, was noted to be above 4.2 mmol/l
less frequently (Table 5) and to rise more rapidly with age
despite a somewhat slower rise in BMI in the DA group
(Additional File 1). It is conceivable then that the liver is
a primary or secondary driver of other observed systemic
changes as has been previously noted [54,55].
The differences observed in the hormonal profiles are also
of interest. Considerable research and community atten-
tion has surrounded DHEAS as a major adrenal androgen
associated with age related changes [56,57]. Its levels may
rise with immune stimulation [58,59]. DHEAS protects
lymphocytes from apoptosis [60] and also LDL particles
from pro-atherogenic oxidation [61]. DHEAS is also ele-
vated by exercise [62] which may be higher in these
patients. There was a suggestion that under 45 years
DHEAS was higher in males and lower in females than
controls (Figure 3) but these did not reach significance.
Larger studies would likely have more statistical power to
detect such alterations.
Similarly IGF1, the mammalian homologue of the inver-
tebrate DAF-16, is one of the main hormones implicated
in insulin – insulin-like-growth-factor signalling (IIS)
pathway in the biology of ageing [63]. It was not possible
to study insulin or C-protein levels as we did not have
access to the fasting state in this group of outpatients.
IGF1 is a key component of the longevity regulation sys-
tem conserved from yeast to mammals, and has recently
been implicated mechanistically in the pathogenesis of
various experimental neurodegenerative disorders
[64,65]. Higher levels of IGF1 in DA in this study are
therefore conceptually provocative.
Whilst this study has the virtue of relatively large numbers
in a single centre, it is not possible to delineate causal
pathways from a purely empirical study of this nature.
Clearly further experimental and clinical work would be
required to formally evaluate this hypothesis. Further-
more it is unclear whether the pharmacology of addiction
itself, or some other related lifestyle factor such as poverty,
homelessness, imprisonment, poor nutrition or overdose
is largely responsible for the observed effects. Nevertheless
the apparent uniformity of results across diverse body sys-
Table 5: Laboratory parameter elevationsSelected results, patients <45 years
PARAMETER Addicts† Medical† %'s* OR CI P
Age <45 Years 739/798 5834/11295 92.6%/51.7% 11.72 8.90–15.47 <0.0001
Body Mass Index >25 148/297 35/53 33.3%/39.8% 0.75 0.46–1.24 N.S.
CRP > 6 IU/l 81/73 490/811 52.6%/37.7% 1.84 1.30–2.60 <0.0005
ESR>30 mm/hr 13/155 49/1159 7.7%/4.1% 1.98 1.00–3.87 <0.05
Globulins >35. g/dl 90/519 503/4930 14.8%/9.3% 1.70 1.32–2.18 <0.0001
Albumin > 42 g/dl 345/264 3000/2433 56.7%/55.2% 1.06 0.89–1.26 N.S.
Globulin/Albumin Ratio >0.9 90/519 503/4930 14.8%/9.3% 1.69 1.21–2.21 <0.002
Albumin/Globulin Ratio >1.8 57/552 495/4938 9.4%/9.1% 1.03 0.76–1.39 N.S.
Lymphocytes >2.5 × 10(9)/l 224/377 1281/2748 37.3%/31.8% 1.27 1.06–1.53 <0.01
ALT > 90 IU/l 105/505 504/4920 17.2%/9.3% 2.03 1.60–2.57 <0.0001
Cholesterol > 4.2 mmol/l 347/263 3593/1872 56.9%/65.8% 0.67 0.56–0.80 <0.0001
Creatinine > 100 mcmol/l 59/679 272/5159 8.0%/5.0% 1.65 1.22–2.23 <0.001
Urea > 5 mmol/l 227/381 1588/3727 37.3%/29.9% 1.41 1.17–1.67 <0.0002
Urea/Creatinine Ratio >6.5 81/658 288/5140 11.0%/5.3% 2.78 2.11–3.65 <0.0001
Creatinine/Urea >22 134/605 1251/4177 18.1%/23.0% 0.74 0.60–0.91 <0.005
IGF1 >30 nmol/l 19/40 21/162 32.2%/11.5% 3.66 1.70–7.91 <0.0002
DHEAS >6 noml/l 30/40 57/109 42.9%/34.3% 1.54 0.78–2.64 N.S.
† – Cells in these columns represent the numbers greater and less than the defined cut-off point.
* – Relates to Percentages in Addicts Vs. Medical Patients
Table 4: Clinical laboratory biomarkers in addiction < 45 years of 
age
ADDICTS MEDICAL P
Age (<45 Years) 30.92 (0.24) 30.74 (0.11) N.S.
CRP(mg/L) 10.15 (2.11) 7.57 (0.55) N.S.
ESR 11.34 (1.29) 8.75 (0.35) 0.05
Albumin(g/L) 42.97 (0.13) 42.80 (0.14) N.S.
Globulins(g/L) 30.33 (0.19) 29.47 (0.05) <0.0001
Albumin/Globulin Ratio 1.45 (0.01) 1.47 (0.00) 0.01
Globulin/Albumin Ratio 0.72 (0.01) 0.69 (0.00) 0.02
Lymphocytes(x10^9/L) 2.41 (0.03) 2.26 (0.01) <0.0001
ALT (U/L) 74.26 (7.99) 51.05 (2.69) <0.01
Cholesterol (mmol/L) 4.48 (0.04) 4.77 (0.14) <0.0001
Urea (mmol/L) 4.76 (0.04) 4.48 (0.19) <0.0001
Creatinine (mcmol/L) 81.93 (0.49) 78.91 (0.27) <0.0001
IGF1 (nmol/l) 25.81 (1.35) 20.79 (0.60) <0.002
DHEAS (mcmol/l) 5.81 (0.44) 4.89 (1.01) N.S.
Mean (± S.E.).Immunity & Ageing 2007, 4:6 http://www.immunityageing.com/content/4/1/6
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Laboratory Parameters of Addiction, All Ages: Part I – Immunity Figure 1
Laboratory Parameters of Addiction, All Ages: Part I – Immunity. A: C-reactive Protein – CRP; B: Erythrocyte Sedimentation 
Rate – ESR; C: Globulins; D: Albumin; E: Albumin Globulin Ratio; F: Lymphocyte Count
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tems is intriguing. A further limitation of this study was
Laboratory Parameters of Addiction, All Ages: Part II – Metabolic Figure 2
Laboratory Parameters of Addiction, All Ages: Part II – Metabolic. A: Alanine Aminotransferase – ALT; B: Cholesterol; C: Urea; 
D: Creatinine; E: DHEAS; F: Insulin Like Growth Factor-1
AB
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DHEAS by addiction status and age and sex groups Figure 3
DHEAS by addiction status and age and sex groups. A: All Ages Both Sexes; B: Males of all ages; C: Females of all ages; D: both 
Sexes <45 Years; E: Males <45 Years; F: Females < 45 Years.
A
F
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DImmunity & Ageing 2007, 4:6 http://www.immunityageing.com/content/4/1/6
Page 9 of 10
(page number not for citation purposes)
the use of medical patients as controls. It would be an
advantage if future funded clinical studies had detailed
information of patients' drug use available for all samples
to allow multivariate association studies to be performed,
and formal assignment of patients' addiction status.
This work would appear to invite further clinical and lab-
oratory based investigations of the dynamic interaction
between addiction and ageing, with the hope that
improved understanding of these related disorders can
improve our clinical management of ageing and addicted
populations, and our understanding of the role of
immune suppression and hyperstimulation in the ageing
process.
Additional material
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